<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33802349</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Inflammasome in ALS Skeletal Muscle: <i>NLRP3</i> as a Potential Biomarker.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2523</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22052523</ELocationID><Abstract><AbstractText>Since NLRP3 inflammasome plays a pivotal role in several neurodegenerative disorders, we hypothesized that levels of inflammasome components could help in diagnosis or prognosis of amyotrophic lateral sclerosis (ALS). Gene and protein expression was assayed by RT-PCR and Western blot. Spearman's correlation coefficient was used to determine the linear correlation of transcriptional expression levels with longevity throughout disease progression in mice models. Kaplan-Meier analysis was performed to evaluate MCC950 effects (NLRP3 inhibitor) on lifespan of SOD1G93A mice. The results showed significant alterations in NLRP3 inflammasome gene and protein levels in the skeletal muscle of SOD1G93A mice. Spearman's correlation coefficient revealed a positive association between <i>Nlrp3</i> transcriptional levels in skeletal muscle and longevity of SOD1G93A mice (r = 0.506; <i>p</i> = 0.027). Accordingly, NLRP3 inactivation with MCC950 decreased the lifespan of mice. Furthermore, <i>NLRP3</i> mRNA levels were significantly elevated in the blood of ALS patients compared to healthy controls (<i>p</i> = 0.03). In conclusion, NLRP3 could be involved in skeletal muscle pathogenesis of ALS, either through inflammasome or independently, and may play a dual role during disease progression. <i>NLRP3</i> gene expression levels could be used as a biomarker to improve diagnosis and prognosis in skeletal muscle from animal models and also to support diagnosis in clinical practice with the blood of ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Garc&#xed;a</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2436-7205</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miana-Mena</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><Identifier Source="ORCID">0000-0001-5981-5448</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Mart&#xed;nez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7277-4318</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Torre</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7955-7164</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEMO (NEuroMuscular Omnicentre) Clinical Center, Fondazione Serena Onlus, Piazza dell'Ospedale Maggiore, 3, 20162 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Genetics Unit, Department of Laboratory Medicine, Niguarda Ca' Granda Hospital, Piazza dell'Ospedale Maggiore, 3, 20162 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaragoza</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Ana Cristina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5687-6704</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS), Calle Miguel Servet 13, 50013, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI17/00949</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>CB18/05/00037</GrantID><Agency>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas</Agency><Country/></Grant><Grant><GrantID>UZ2018-BIO-03</GrantID><Agency>Universidad de Zaragoza</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005663">Furans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007192">Indenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>6RS86E2BWQ</RegistryNumber><NameOfSubstance UI="C000597426">N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007192" MajorTopicYN="N">Indenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS patients</Keyword><Keyword MajorTopicYN="N">NLRP3</Keyword><Keyword MajorTopicYN="N">SOD1G93A</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">blood</Keyword><Keyword MajorTopicYN="N">inflammasome</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>3</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33802349</ArticleId><ArticleId IdType="pmc">PMC7959138</ArticleId><ArticleId IdType="doi">10.3390/ijms22052523</ArticleId><ArticleId IdType="pii">ijms22052523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Calvo A.C., Manzano R., Mendon&#xe7;a D.M., Mu&#xf1;oz M.J., Zaragoza P., Osta R. Amyotrophic Lateral Sclerosis: A Focus on Disease Progression. BioMed Res. Int. 2014;2014:925101. doi: 10.1155/2014/925101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/925101</ArticleId><ArticleId IdType="pmc">PMC4137497</ArticleId><ArticleId IdType="pubmed">25157374</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.F., Dib M. Biomarkers in amyotrophic lateral sclerosis: Facts and future horizons. Mol. Diagn. Ther. 2009;13:115&#x2013;125. doi: 10.1007/BF03256320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03256320</ArticleId><ArticleId IdType="pubmed">19537846</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Vourc&#x2019;h P., Pradat P.F., Gordon P.H., Andres C.R., Corcia P. Further development of biomarkers in amyotrophic lateral sclerosis. Expert Rev. Mol. Diagn. 2016;16:853&#x2013;868. doi: 10.1080/14737159.2016.1199277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2016.1199277</ArticleId><ArticleId IdType="pubmed">27275785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. The Role of immune and inflammatory mechanisms in ALS. Curr Mol. Med. 2011;11:246&#x2013;254. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Debye B., Schm&#xfc;lling L., Zhou L., Rune G., Beyer C., Johann S. Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice. Brain Pathol. 2018;28:14&#x2013;27. doi: 10.1111/bpa.12467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12467</ArticleId><ArticleId IdType="pubmed">27880990</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A., Giacoppo S., Bramanti P., Mazzon E. NLRP3 Inflammasome Activation in a Transgenic Amyotrophic Lateral Sclerosis Model. Inflammation. 2018;41:93&#x2013;103. doi: 10.1007/s10753-017-0667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0667-5</ArticleId><ArticleId IdType="pubmed">28936769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim H., Deltenre P., Martin J.J., S&#xe9;bire G. In-situ expression of Interleukin-18 and associated mediators in the human brain of sALS patients: Hypothesis for a role for immune-inflammatory mechanisms. Med. Hypotheses. 2016;86:14&#x2013;17. doi: 10.1016/j.mehy.2015.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2015.11.022</ArticleId><ArticleId IdType="pubmed">26804591</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S., Heitzer M., Kanagaratnam M., Goswami A., Rizo T., Weis J., Troost D., Beyer C. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63:2260&#x2013;2273. doi: 10.1002/glia.22891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22891</ArticleId><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Martin L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010;19:2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll R.C., Robertson A.A.B., Chae J.J., Higgins S.C., Mu&#xf1;oz-Planillo R., Inserra M.C., Vetter I., Dungan L.S., Monks B.G., Stutz A., et al. A small molecule inhibitior of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases. Nat. Med. 2015;21:248&#x2013;255. doi: 10.1038/nm.3806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3806</ArticleId><ArticleId IdType="pmc">PMC4392179</ArticleId><ArticleId IdType="pubmed">25686105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Abell&#xe1;n A., Angosto-Bazarra D., Mart&#xed;nez-Banaclocha H., de Torre-Minguela C., Cer&#xf3;n-Carrasco J.P., P&#xe9;rez-S&#xe1;nchez H., Arostegui J.I., Pelegrin P. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat. Chem. Biol. 2019;15:560&#x2013;564. doi: 10.1038/s41589-019-0278-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-019-0278-6</ArticleId><ArticleId IdType="pmc">PMC7116292</ArticleId><ArticleId IdType="pubmed">31086329</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll R.C., Hill J.R., Day C.J., Zamoshnikova A., Boucher D., Massey N.L., Chitty J.L., Fraser J.A., Jennings M.P., Robertson A.A.B., et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat. Chem. Biol. 2019;15:556&#x2013;559. doi: 10.1038/s41589-019-0277-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-019-0277-7</ArticleId><ArticleId IdType="pubmed">31086327</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyke J.M., Smit-Oistad I.M., Macrander C., Krakora D., Meyer M.G., Suzuki M. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS) Exp. Neurol. 2016;277:275&#x2013;282. doi: 10.1016/j.expneurol.2016.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.01.008</ArticleId><ArticleId IdType="pmc">PMC4762214</ArticleId><ArticleId IdType="pubmed">26775178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S., Esch E., Hartmann P., Goswami A., Nikolin S., Weis J., Beyer C., Johann S. Expression profile of pattern recognition receptors in skeletal muscle of SOD1(G93A) amyotrophic lateral sclerosis (ALS) mice and sporadic ALS patients. Neuropathol. Appl. Neurobiol. 2018;44:606&#x2013;627. doi: 10.1111/nan.12483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12483</ArticleId><ArticleId IdType="pubmed">29575052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillon N.J., Krook A. Innate immune receptors in skeletal muscle metabolism. Exp. Cell Res. 2017;360:47&#x2013;54. doi: 10.1016/j.yexcr.2017.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2017.02.035</ArticleId><ArticleId IdType="pubmed">28232117</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost R.A., Lang C.H. Regulation of muscle growth by pathogen-associated molecules. J. Anim Sci. 2008;86:E84&#x2013;E93. doi: 10.2527/jas.2007-0483.</Citation><ArticleIdList><ArticleId IdType="doi">10.2527/jas.2007-0483</ArticleId><ArticleId IdType="pubmed">18192560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura M., Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol. Pharm. Bull. 2005;28:886&#x2013;892. doi: 10.1248/bpb.28.886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.28.886</ArticleId><ArticleId IdType="pubmed">15863899</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Khan A.A., Srivastava R., Llewellyn K.J., Tan B., Shukr N., Fazli Y., Kimonis V.E., BenMohamed L. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy. Inflammation. 2017;40:21&#x2013;41. doi: 10.1007/s10753-016-0449-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-016-0449-5</ArticleId><ArticleId IdType="pmc">PMC5800525</ArticleId><ArticleId IdType="pubmed">27730320</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg I., Kratz A.K., Alexanderson H., Patarroyo M. Decreased expression of interleukin-1&#x3b1;, interleukin-1&#x3b2;, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2000;43:336&#x2013;348. doi: 10.1002/1529-0131(200002)43:2&lt;336::AID-ANR13&gt;3.0.CO;2-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200002)43:2&lt;336::AID-ANR13&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">10693873</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride M.J., Foley K.P., D&#x2019;Souza D.M., Li Y.E., Lau T.C., Hawke T.J., Schertzer J.D. The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am. J. Physiol. Endocrinol. Metab. 2017;313:E222&#x2013;E232. doi: 10.1152/ajpendo.00060.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00060.2017</ArticleId><ArticleId IdType="pmc">PMC5582883</ArticleId><ArticleId IdType="pubmed">28536183</ArticleId></ArticleIdList></Reference><Reference><Citation>Boursereau R., Abou-Samra M., Lecompte S., Noel L., Brichard S.M. Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy. BMC Biol. 2018;16:33. doi: 10.1186/s12915-018-0501-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-018-0501-z</ArticleId><ArticleId IdType="pmc">PMC5861675</ArticleId><ArticleId IdType="pubmed">29558930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., Niu F., Chen J., Cao X., Liu Z., Bao X., Xu Y. Ghrelin improves muscle function in dystrophin-deficient mdx mice by inhibiting NLRP3 inflammasome activation. Life Sci. 2019;232:116654. doi: 10.1016/j.lfs.2019.116654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.116654</ArticleId><ArticleId IdType="pubmed">31306657</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N., Kny M., Riediger F., Busch K., Schmidt S., Luft F.C., Slevogt H., Fielitz J. Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy. Intensive Care Med. Exp. 2017;5:3. doi: 10.1186/s40635-016-0115-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-016-0115-0</ArticleId><ArticleId IdType="pmc">PMC5241267</ArticleId><ArticleId IdType="pubmed">28097512</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012;13:227&#x2013;232. doi: 10.1038/nrg3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3185</ArticleId><ArticleId IdType="pmc">PMC3654667</ArticleId><ArticleId IdType="pubmed">22411467</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 2003;4:117. doi: 10.1186/gb-2003-4-9-117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2003-4-9-117</ArticleId><ArticleId IdType="pmc">PMC193646</ArticleId><ArticleId IdType="pubmed">12952525</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A.C., Manzano R., Atencia-Cibreiro G., Oliv&#xe1;n S., Mu&#xf1;oz M.J., Zaragoza P., Cordero-V&#xe1;zquez P., Esteban-P&#xe9;rez J., Garc&#xed;a-Redondo A., Osta R. Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice. PLoS ONE. 2012;7:e32632. doi: 10.1371/journal.pone.0032632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032632</ArticleId><ArticleId IdType="pmc">PMC3296719</ArticleId><ArticleId IdType="pubmed">22412900</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A.C., Atencia-Cibreiro G., Torre Merino P., Roy J.F., Galiana A., Ju&#xe1;rez Rufi&#xe1;n A., Cano J.M., Mart&#xed;n M.A., Moreno L., Larrod&#xe9; P., et al. Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis. Aging Dis. 2019;10:278&#x2013;292. doi: 10.14336/AD.2018.0917.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2018.0917</ArticleId><ArticleId IdType="pmc">PMC6457048</ArticleId><ArticleId IdType="pubmed">31011479</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll R.C., O&#x2019;Neill L., Schroder K. Questions and controversies in innate immune research: What is the physiological role of NLRP3? Cell Death Discov. 2016;2:16019. doi: 10.1038/cddiscovery.2016.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddiscovery.2016.19</ArticleId><ArticleId IdType="pmc">PMC4979470</ArticleId><ArticleId IdType="pubmed">27551512</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora V., Lee J.D., Albornoz E.A., McAlary L., Jagaraj C.J., Robertson A.A.B., Atkin J.D., Cooper M.A., Schroder K., Yerbury J.J., et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 2020;68:407&#x2013;421. doi: 10.1002/glia.23728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23728</ArticleId><ArticleId IdType="pubmed">31596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F., Molawi K., Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. USA. 2010;107:13046&#x2013;13050. doi: 10.1073/pnas.1002396107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Parisi C., Matteucci A., Potenza R.L., Armida M., Popoli P., D&#x2019;Ambrosi N., Volont&#xe9; C. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis. Model. Mech. 2014;7:1101&#x2013;1109. doi: 10.1242/dmm.017038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.017038</ArticleId><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett R., Sluyter V., Watson D., Sluyter R., Yerbury J.J. P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1 G93A amyotrophic lateral sclerosis mice. PeerJ. 2017;5:e3064. doi: 10.7717/peerj.3064.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.3064</ArticleId><ArticleId IdType="pmc">PMC5335685</ArticleId><ArticleId IdType="pubmed">28265522</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Montilli C., Volont&#xe9; C., D&#x2019;ambrosi N. Ablation of p2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:4102&#x2013;4116. doi: 10.1093/hmg/ddt259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt259</ArticleId><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M.S., Yu J.T., Jiang T., Zhu X.C., Tan L. The NLRP3 inflammasome in Alzheimer&#x2019;s disease. Mol. Neurobiol. 2013;48:875&#x2013;882. doi: 10.1007/s12035-013-8475-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8475-x</ArticleId><ArticleId IdType="pubmed">23686772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb R., Liu G.H., Janowski A.M., Sutterwala F.S., Zhang W. Inflammasomes in cancer: A double-edged sword. Protein Cell. 2014;5:12&#x2013;20. doi: 10.1007/s13238-013-0001-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-013-0001-4</ArticleId><ArticleId IdType="pmc">PMC3938856</ArticleId><ArticleId IdType="pubmed">24474192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.X., Shi K.H. NLRP3, a Double-edged Sword in Lung Injury Diseases. Inflammation. 2015;38:1855&#x2013;1856. doi: 10.1007/s10753-015-0163-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-015-0163-8</ArticleId><ArticleId IdType="pubmed">25899804</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves Cambui R.A., Ferreira do Esp&#xed;rito Santo G., Pereira Fernandes F., Vinicius Nunes C.L., Borsatto Galera B., Palacio F&#xe1;varo E.G., Amorim Rizzo L., Elias R.M., Pontillo A. Double-edged sword of inflammasome genetics in colorectal cancer prognosis. Clin. Immunol. 2020;213:108373. doi: 10.1016/j.clim.2020.108373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108373</ArticleId><ArticleId IdType="pubmed">32135277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q., Gao W., Loughran P., Shapiro R., Fan J., Billiar T.R., Scott M.J. Caspase 1 activation is protective against hepatocyte cell death by up-regulating beclin 1 protein and mitochondrial autophagy in the setting of redox stress. J. Biol. Chem. 2013;288:15947&#x2013;15958. doi: 10.1074/jbc.M112.426791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.426791</ArticleId><ArticleId IdType="pmc">PMC3668750</ArticleId><ArticleId IdType="pubmed">23589298</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M., R&#xfc;egg A., Werner S., Beer H.D. Active Caspase-1 Is a Regulator of Unconventional Protein Secretion. Cell. 2008;132:818&#x2013;831. doi: 10.1016/j.cell.2007.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.12.040</ArticleId><ArticleId IdType="pubmed">18329368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis. Immunity. 2010;32:379&#x2013;391. doi: 10.1016/j.immuni.2010.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.03.003</ArticleId><ArticleId IdType="pmc">PMC2982187</ArticleId><ArticleId IdType="pubmed">20303296</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruchard M., Reb&#xe9; C., Derang&#xe8;re V., Togb&#xe9; D., Ryffel B., Boidot R., Humblin E., Hamman A., Chalmin F., Berger H., et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat. Immunol. 2015;16:859&#x2013;870. doi: 10.1038/ni.3202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3202</ArticleId><ArticleId IdType="pubmed">26098997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting J.P.Y., Harton J.A. NLRP3 moonlights in TH2 polarization. Nat. Immunol. 2015;16:794&#x2013;796. doi: 10.1038/ni.3223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3223</ArticleId><ArticleId IdType="pubmed">26194278</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Gao X., Miao Y., Wang Y., Wang H., Cheng Z., Wang X., Jing X., Jia L., Dai L., et al. NLRP3 regulates macrophage M2 polarization through up-regulation of IL-4 in asthma. Biochem. J. 2018;475:1995&#x2013;2008. doi: 10.1042/BCJ20180086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20180086</ArticleId><ArticleId IdType="pubmed">29626160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruchard M., Boidot R., Ghiringhelli F., V&#xe9;gran F. Transcriptome analysis of TH2 CD4+ T cells differentiated from wild-type and NLRP3KO mice. Genom. Data. 2015;5:314&#x2013;315. doi: 10.1016/j.gdata.2015.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gdata.2015.06.031</ArticleId><ArticleId IdType="pmc">PMC4583695</ArticleId><ArticleId IdType="pubmed">26484275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kugelberg E. T cell differentiation: NLRP3 goes beyond the inflammasome. Nat. Rev. Immunol. 2015;15:467. doi: 10.1038/nri3886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3886</ArticleId><ArticleId IdType="pubmed">26160614</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsley V., Jansen K.M., Mills S.T., Pavlath G.K. IL-4 Acts as a Myoblast Recruitment Factor during Mammalian Muscle Growth. Cell. 2003;113:483&#x2013;494. doi: 10.1016/S0092-8674(03)00319-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00319-2</ArticleId><ArticleId IdType="pubmed">12757709</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng J., Zou X., Wu R., Zhong R., Zhu D., Zhang Y. Accelerated regeneration of the skeletal muscle in RNF13-knockout mice is mediated by macrophage-secreted IL-4/IL-6. Protein Cell. 2014;5:235&#x2013;247. doi: 10.1007/s13238-014-0025-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0025-4</ArticleId><ArticleId IdType="pmc">PMC3967074</ArticleId><ArticleId IdType="pubmed">24563216</ArticleId></ArticleIdList></Reference><Reference><Citation>Raimondo T.M., Mooney D.J. Functional muscle recovery with nanoparticle-directed M2 macrophage polarization in mice. Proc. Natl. Acad. Sci. USA. 2018;115:10648&#x2013;10653. doi: 10.1073/pnas.1806908115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1806908115</ArticleId><ArticleId IdType="pmc">PMC6196479</ArticleId><ArticleId IdType="pubmed">30275293</ArticleId></ArticleIdList></Reference><Reference><Citation>Francos-Quijorna I., Amo-Aparicio J., Martinez-Muriana A., L&#xf3;pez-Vales R. IL-4 Drives Microglia and Macrophages Toward a Phenotype Conducive for Tissue Repair and Functional Recovery After Spinal Cord Injury. Glia. 2016;64:2079&#x2013;2092. doi: 10.1002/glia.23041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23041</ArticleId><ArticleId IdType="pubmed">27470986</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi C., Cusimano M., Zambito M., Finardi A., Capotondo A., Garcia-Manteiga J.M., Comi G., Furlan R., Martino G., Muzio L. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis. 2018;9:250. doi: 10.1038/s41419-018-0288-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0288-4</ArticleId><ArticleId IdType="pmc">PMC5833860</ArticleId><ArticleId IdType="pubmed">29445154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P., Apolloni S., Bianchi A., Salvatori I., Valle C., Lanzuolo C., Bendotti C., Nardo G., Volont&#xe9; C. P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Brain Pathol. 2020;30:272&#x2013;282. doi: 10.1111/bpa.12774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12774</ArticleId><ArticleId IdType="pmc">PMC7065186</ArticleId><ArticleId IdType="pubmed">31376190</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini A., Capece M., Chiozzi P., Falzoni S., Sanz J.M., Sarti A.C., Bonora M., Pinton P., Di Virgilio F. The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein. FASEB J. 2015;29:2450&#x2013;2461. doi: 10.1096/fj.14-268714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-268714</ArticleId><ArticleId IdType="pubmed">25690658</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Virgilio F. The Therapeutic Potential of Modifying Inflammasomes and NOD-Like Receptors. Pharm. Rev. 2013;65:872&#x2013;905. doi: 10.1124/pr.112.006171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.112.006171</ArticleId><ArticleId IdType="pubmed">23592611</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinstein L., Endter K., Hedrich C.M., Reinke S., Luksch H., Schulze F., Robertson A.A.B., Cooper M.A., R&#xf6;sen-Wolff A., Winkler S. An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes. Clin. Immunol. 2018;191:100&#x2013;109. doi: 10.1016/j.clim.2017.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.11.011</ArticleId><ArticleId IdType="pubmed">29183866</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitzer M., Kaiser S., Kanagaratnam M., Zendedel A., Hartmann P., Beyer C., Johann S. Administration of 17&#x3b2;-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice. Mol. Neurobiol. 2017;54:8429&#x2013;8443. doi: 10.1007/s12035-016-0322-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0322-4</ArticleId><ArticleId IdType="pubmed">27957680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E. Transgenic-mouse model of amyotrophic lateral sclerosis. N. Engl. J. Med. 1994;331:1721&#x2013;1722. doi: 10.1056/NEJM199412223312516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199412223312516</ArticleId><ArticleId IdType="pubmed">7832899</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliv&#xe1;n S., Calvo A.C., Rando A., Mu&#xf1;oz M.J., Zaragoza P., Osta R. Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Exp. Anim. 2015;64:147&#x2013;153. doi: 10.1538/expanim.14-0077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1538/expanim.14-0077</ArticleId><ArticleId IdType="pmc">PMC4427729</ArticleId><ArticleId IdType="pubmed">25736480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey C., Rubio Araiz A., Bryson K.J., Finucane O., Larkin C., Mills E.L., Robertson A.A.B., Cooper M.A., O&#x2019;Neill L.A.J., Lynch M.A. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-&#x3b2; and cognitive function in APP/PS1 mice. Brain Behav. Immun. 2017;61:306&#x2013;316. doi: 10.1016/j.bbi.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.12.014</ArticleId><ArticleId IdType="pubmed">28003153</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>